{"id":336604,"date":"2019-03-05T01:00:00","date_gmt":"2019-03-05T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/hope-for-patients-with-her2-positive-breast-cancer-and-invasive-residual-disease\/"},"modified":"2019-03-05T01:00:00","modified_gmt":"2019-03-05T00:00:00","slug":"hope-for-patients-with-her2-positive-breast-cancer-and-invasive-residual-disease","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/hope-for-patients-with-her2-positive-breast-cancer-and-invasive-residual-disease\/","title":{"rendered":"Hope for patients with HER2-positive breast cancer and invasive residual disease"},"content":{"rendered":"<p><strong>If complete remission cannot be achieved in patients with HER2-positive breast cancer despite exhausting current treatment options, the risk of recurrence is high. Results from an open-label phase III trial of trastuzumab emtansine raise hope.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>For the open-label phase III trial, 1486 patients with HER2-positive breast cancer who had invasive residual disease despite neoadjuvant chemotherapy, as well as HER2-targeted therapy and subsequent surgery, were studied. Randomized 1:1, they received 14 cycles of the antibody-drug conjugate, consisting of the microtubule inhibitor DM1-bound HER2-targeting monoclonal antibody trastuzumab emtansine (T-DM1), or trastuzumab for 12 weeks. The primary endpoint was defined as invasive disease-free survival (IDFS).<\/p>\n<p>Analysis of the results showed that T-DM1 significantly improved IDFS over trastuzumab. A total of 256 IDFS events were recorded, including 91 (12.2%) in the T-DM1 regimen and 165 (22.2%) in the control group (unstratified hazard ratio (HR): 0.50; 95% confidence interval (CI): 0.39-0.64; p&lt;0.0001). The evaluation in terms of overall survival is still pending. In this regard, a longer follow-up phase will provide more detailed insights.<\/p>\n<p>\n<em>Source: Geyer Jr CE, et al: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. Abstract GS1_10, SABCS 2018<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONCOLOGY &amp; HEMATOLOGY 2019; 7(1): 32.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>If complete remission cannot be achieved in patients with HER2-positive breast cancer despite exhausting current treatment options, the risk of recurrence is high. Results from an open-label phase III trial&hellip;<\/p>\n","protected":false},"author":7,"featured_media":87069,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"San Antonio Breast Cancer Symposium","footnotes":""},"category":[11513,11400,11370,11548,11503],"tags":[13554,13561],"powerkit_post_featured":[],"class_list":["post-336604","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-gynecology","category-oncology","category-rx-en","category-studies","tag-breast-cancer-en","tag-breast-cancer-en-2","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-03 18:50:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":336609,"slug":"espoir-pour-les-patientes-atteintes-dun-cancer-du-sein-her2-positif-et-dune-maladie-residuelle-invasive","post_title":"Espoir pour les patientes atteintes d'un cancer du sein HER2-positif et d'une maladie r\u00e9siduelle invasive","href":"https:\/\/medizinonline.com\/fr\/espoir-pour-les-patientes-atteintes-dun-cancer-du-sein-her2-positif-et-dune-maladie-residuelle-invasive\/"},"it_IT":{"locale":"it_IT","id":336611,"slug":"speranza-per-le-pazienti-con-tumore-al-seno-her2-positivo-e-malattia-invasiva-residua","post_title":"Speranza per le pazienti con tumore al seno HER2-positivo e malattia invasiva residua","href":"https:\/\/medizinonline.com\/it\/speranza-per-le-pazienti-con-tumore-al-seno-her2-positivo-e-malattia-invasiva-residua\/"},"pt_PT":{"locale":"pt_PT","id":336618,"slug":"esperanca-para-doentes-com-cancro-da-mama-her2-positivo-e-doenca-residual-invasiva","post_title":"Esperan\u00e7a para doentes com cancro da mama HER2-positivo e doen\u00e7a residual invasiva","href":"https:\/\/medizinonline.com\/pt-pt\/esperanca-para-doentes-com-cancro-da-mama-her2-positivo-e-doenca-residual-invasiva\/"},"es_ES":{"locale":"es_ES","id":336593,"slug":"esperanza-para-las-pacientes-con-cancer-de-mama-her2-positivo-y-enfermedad-invasiva-residual","post_title":"Esperanza para las pacientes con c\u00e1ncer de mama HER2-positivo y enfermedad invasiva residual","href":"https:\/\/medizinonline.com\/es\/esperanza-para-las-pacientes-con-cancer-de-mama-her2-positivo-y-enfermedad-invasiva-residual\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/336604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=336604"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/336604\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/87069"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=336604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=336604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=336604"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=336604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}